Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells

• Linglong Yin,
• Youhong Liu,
• Yuchong Peng,
• Yongbo Peng,
• Xiaohui Yu,
• Yingxue Gao,
• Bowen Yuan,
• Qianling Zhu,
• Tuoyu Cao,
• Leye He,
• Zhicheng Gong,
• Lunquan Sun,
• Xuegong Fan,
• Xiong Li

Affiliations

Linglong Yin

Center for Molecular Medicine, Xiangya Hospital, Central South University

Youhong Liu

Center for Molecular Medicine, Xiangya Hospital, Central South University

Yuchong Peng

Center for Molecular Medicine, Xiangya Hospital, Central South University

Yongbo Peng

State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University

Xiaohui Yu

Center for Molecular Medicine, Xiangya Hospital, Central South University

Yingxue Gao

Center for Molecular Medicine, Xiangya Hospital, Central South University

Bowen Yuan

Center for Molecular Medicine, Xiangya Hospital, Central South University

Qianling Zhu

Center for Molecular Medicine, Xiangya Hospital, Central South University

Tuoyu Cao

Center for Molecular Medicine, Xiangya Hospital, Central South University

Leye He

Research Institute for Prostate Disease, Central South University

Zhicheng Gong

Department of Pharmacy, Xiangya Hospital, Central South University

Lunquan Sun

Center for Molecular Medicine, Xiangya Hospital, Central South University

Xuegong Fan

Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University

Xiong Li

Center for Molecular Medicine, Xiangya Hospital, Central South University